Bryan Giraudo sold $5.9M of PTGX
director at Protagonist Therapeutics, Inc. 59,130 shares at an average of $100.10, traded May 7, 2026, filed May 11, 2026.
Score components
- +15RoleDirector
- +25Trade size$5.9M at market
- +20Share of holdings soldSold 93% of holdings
- +8Cluster2 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +2.2%, 3m +44.9%, 6m -.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001104659-26-058860, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| May 7, 2026 | MOption exercise Common Stock | +24,000 | $6.45 | $155k | 31,825 | May 11, 2026 |
| May 7, 2026 | MOption exercise Common Stock | +12,000 | $6.98 | $84k | 43,825 | May 11, 2026 |
| May 7, 2026 | SOpen-market sale Common Stock | -36,000 | $100.14 | $3.6M | 27,825 | May 11, 2026 |
| May 7, 2026 | SOpen-market sale Common Stockindirect: By Bryan & Courtney Giraudo Trust | -12,000 | $100.07 | $1.2M | 6,000 | May 11, 2026 |
| May 8, 2026 | SOpen-market sale Common Stockindirect: By Bryan & Courtney Giraudo Trust | -6,000 | $100.00 | $600k | 0 | May 11, 2026 |
| May 8, 2026 | SOpen-market sale Common Stock | -5,130 | $100.00 | $513k | 12,695 | May 11, 2026 |
| May 7, 2026 | MOption exercise Stock Option (right to buy)derivative | -24,000 | $0.00 | $0 | 0 | May 11, 2026 |
| May 7, 2026 | MOption exercise Stock Option (right to buy)derivative | -12,000 | $0.00 | $0 | 0 | May 11, 2026 |
Related signals
Other insiders at Protagonist Therapeutics, Inc and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 22Weak | Protagonist Therapeutics, Inc | Asif Ali Chief Financial Officer | $8.3M 58,629 shares | -50% | |
| 20Weak | Protagonist Therapeutics, Inc | Dinesh Ph D Patel V President and CEO | $18M 125,000 shares | -22% | |
| 20Weak | Protagonist Therapeutics, Inc | Dinesh Ph D Patel V President and CEO | $15M 100,000 shares | -17% | |
| 25Weak | Protagonist Therapeutics, Inc | William D. Waddill director | $1.1M 9,000 shares | -53% | |
| 25Weak | Protagonist Therapeutics, Inc | William D. Waddill director | $969k 9,000 shares | -53% | |
| 24Weak | Protagonist Therapeutics, Inc | William D. Waddill director | $897k 9,000 shares | -53% | |
| 28Weak | Protagonist Therapeutics, Inc | Dinesh Ph D Patel V President and CEO | $7.5M 75,000 shares | -13% | |
| 48Moderate | Protagonist Therapeutics, Inc | Dinesh Ph D Patel V President and CEO | $7.5M 75,000 shares | -13% | |
| 34Weak | PTGXsell Protagonist Therapeutics, Inc | Asif Ali Chief Financial Officer | $185k 1,750 shares | -3% | |
| 57Moderate | Protagonist Therapeutics, Inc | Asif Ali Chief Financial Officer | $2.6M 24,765 shares | -29% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.